DAX25.421 +0,1%Est506.030 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,61 +1,6%Nas23.710 -0,1%Bitcoin81.550 -0,3%Euro1,1651 ±0,0%Öl65,11 -0,5%Gold4.638 +1,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 DroneShield A2DMAA BioNTech (ADRs) A2PSR2 Siemens Energy ENER6Y Bayer BAY001 RENK RENK73 Infineon 623100 Lufthansa 823212 SAP 716460 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas tiefer erwartet -- Asiens Börsen mehrheitlich in Grün - Nikkei erstmals über 54.000 Punkte -- Alibaba, NVIDIA im Fokus
Top News
Der neue TikTok-Channel von finanzen.net ist da - jetzt abonnieren! Der neue TikTok-Channel von finanzen.net ist da - jetzt abonnieren!
NVIDIA-Aktie im Aufwind: US-Exportgenehmigung für China und Milliarden-Deal mit Eli Lilly NVIDIA-Aktie im Aufwind: US-Exportgenehmigung für China und Milliarden-Deal mit Eli Lilly
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Neurocrine Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
112,10 EUR -1,20 EUR -1,06 %
STU
132,10 USD -0,13 USD -0,10 %
nachbörslich
BTT
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.11,36 Mrd. EUR

KGV41,47Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN900964

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS64125C1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBIX

Neurocrine Biosciences Aktien News

DatumMeistgelesen
PR NewswireNeurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
PR NewswireNeurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
PR NewswireNeurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
PR NewswireNeurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
PR NewswireNeurocrine Biosciences to Participate at Virtual Investor Conferences in March
PR NewswireNeurocrine Biosciences to Participate at Investor Conferences in March
PR NewswireNeurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
PR NewswireNeurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireNeurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
PR NewswireNeurocrine Biosciences to Host Analyst Day on December 5, 2023
PR NewswireNeurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
PR NewswireNeurocrine Biosciences Provides Development Pipeline Update
PR NewswireNeurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
PR NewswireNeurocrine Biosciences to Present at the Jefferies London Healthcare Conference
PR NewswireNeurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Stu...
PR NewswireNeurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results
PR NewswireNeurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints
PR NewswireNeurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA® (valbenazine) Oral Granules Sprinkle Formulation
PR NewswireNeurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)
PR NewswireNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
PR NewswireNeurocrine Biosciences Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders® Demonstrating Comparable Improvement Over Time in Tardive Dyskinesia Severity and ...
PR NewswireNeurocrine Biosciences Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease
PR NewswireNeurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease
PR NewswireNeurocrine Biosciences Reports Second Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance
PR NewswireNeurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2023 Financial Results
PR NewswireDiurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023
PR NewswireNeurocrine Biosciences to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
PR NewswireNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate
PR NewswireNeurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology
PR NewswireNeurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective D...
PR NewswireNeurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
PR NewswireNeurocrine Biosciences Reports First Quarter 2023 Financial Results
PR NewswireNeurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference
PR NewswireNeurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week

Neurocrine Biosciences News

Neurocrine Biosciences News: auf dieser Seite finden Sie alle Neurocrine Biosciences News und Nachrichten zur Neurocrine Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Neurocrine Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Neurocrine Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.